medigraphic.com
Colegio de Medicos y Cirujanos República de Costa Rica

2012, Number 604

<< Back Next >>

Rev Med Cos Cen 2012; 69 (604)

Virus del papiloma E indicaciones de la vacuna tetravalente

Vargas MSF, Estrada RC

Language: Spanish
References: 13
Page: 455-459
PDF size: 196.95 Kb.


ABSTRACT

The human papilloma virus is one of the most common sexually transmitted infections; it is associated with various diseases covering from cervical and anal cancer, to genital warms. Its peculiar immunologic features allow it to persist in some patients and cause malignant diseases. With the approbation of the tetravalent vaccine against the HPV the physicians own a new weapon in primary prevention against cervical cancer, genital warms and anal cancer. This work reviews the actual knowledge and indications of this vaccine in the general practice.


REFERENCES

  1. Brady, M y otros (2012); HPV Vaccine Recommendation, Committee on infectious diseases; Pediatrics; 129: 602- 605.

  2. Diaz, M (2008),Human Papilloma Virus – Prevention and Treatment; Obstetrics and Gynecology Clinics of North America; 35:199–217

  3. 3. Douglas. J (2011); Papilloma virus; Goldman’s Cecil Medicine; 2121-2125.

  4. Dunne E, Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males, Advisory Committee on Immunization Practices; Morbidity and Mortality Wekly Report. 2011;(50):1705–1708

  5. Einstein.M y otros (2009); Clinician’s guide to human papillomavirus immunology: knowns and unknowns; Lancet Infectious Diseases; 9: 347–56.

  6. Hager. D (2009); Human Papilloma Virus Infection and Prevention in the Adolescent Population; Journal of Pediatric and Adolescent Gynecology; 22:197-204

  7. Kim.J(2010);Targeted human papillomavirus vaccination of men who have sex with men in the USA: a costeffectiveness modelling analysis; Lancet Infectious Diseases;10: 845–52.

  8. Knudtson. M, Tiso. S, Phillips. S (2009); Human Papillomavirus and the HPV Vaccine: Are the Benefits Worth the Risks? ; Nursing Clinics of North America; 44: 293–299.

  9. Leddy. M, Anderson. B, Gall. S, MD, Schulkin, J(2009); Obstetriciangynecologists and the HPV Vaccine: Practice Patterns, Beliefs, and Knowledge, Journal of Pediatric and Adolescent Gynecology; 22: 239-246

  10. Markowitz L, Dunne E, Saraiya M(2007); Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices; Morbidity and Mortality Wekly Report ; 56:1-24.

  11. Vaughn. J, Miller, R (2011)Update on Immunizations in Adults, American Family Physician.;84:1015-1020.

  12. Waxman. A, Zsemlye. M (2008);Preventing Cervical Cancer: The Pap Test and the HPV Vaccine; Medical Clinics of North America; 92:1059– 1082

  13. Wheeler. C.M, (2008); Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer. Obstetrics and Gynecology Clinics of North America; 35 519–536




2020     |     www.medigraphic.com